Bibliography
- Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24(3):181-91
- Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000;283(3):367-72
- FDA approves Relistor for opioid-induced constipation. Drug will help reduce effects of drugs like morphine on bowel function. FDA, Washington, DC; 2008. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116885.htm [Last accessed 23 May 2013]
- Yuan CS, Foss JF, Osinski J, et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 1997;61(4):467-75
- Oral Relistor may ease bowel back-up from opiates. medPage Today, New York, NY; 2012. Available from: http://www.medpagetoday.com/MeetingCoverage/DDW/32947 [Last accessed 23 May 2013]
- Lin DH, Wang CZ, Qin LF, et al. Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. Drug Dev Ind Pharm 2013; doi:10.3109/03639045.2012.753899
- Naloxegol (NKTR-118) and NKTR-119. nektar, San Francisco, CA; 2013. Available from: http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html [Last accessed 23 May 2013]
- Phase 2 data from oral NKTR-118 presented at American College of Gastroenterology in San Diego. drugs.com, Auckland, New Zealand; 2009. Available from: http://www.drugs.com/clinical_trials/phase-2-data-oral-nktr-118-presented-american-college-gastroenterology-san-diego-8320.html [Last accessed 23 May 2013]
- Yuan CS. Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 2007;41(6):984-93
- FDA approves Entereg to speed bowel recovery. Drug approved for limited use in adults following resection surgery. medNet Medical, Encino, CA; 2008. Available from: http://www.modernmedicine.com/modern-medicine/news/modernmedicine/welcome-modernmedicine/fda-approves-entereg-speed-bowel-recovery [Last accessed 23 May 2013]
- GSK and Adolor announce preliminary results from phase 3 Safety study of Alvimopan (Entereg/Entrareg). Current development program for OBD on hold while findings from long-term safety study are evaluated. glaxoSmithKline, Middlesex, UK; 2007. Available from: http://www.gsk.com/media/press-releases/2007/gsk-and-adolor-announce-preliminary-results-from-phase-3-safety-study-of-alvimopan-enteregentrareg.html [Last accessed 23 May 2013]
- Mehendale SR, Yuan CS. Opioid-induced gastrointestinal dysfunction. Dig Dis 2006;24(1-2):105-12
- Lacy BE, Chey WD. Lubiprostone: chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother 2009;10(1):143-52
- Sucampo gets FDA approval for supplemental NDA for Amitiza to treat OIC. The Wall Street Journal, New York, NY; 2013. Available from: http://online.wsj.com/article/BT-CO-20130423-705544.html [Last accessed 23 May 2013]
- Murphy DB, Sutton JA, Prescott LF, et al. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997;87(4):765-70